Nexstim 将来の成長

Future 基準チェック /46

Nexstimは、75.1%と15.7%でそれぞれ年率75.1%で利益と収益が成長すると予測される一方、EPSはgrowで75.6%年率。

主要情報

75.1%

収益成長率

75.6%

EPS成長率

Medical Equipment 収益成長	14.2%
収益成長率	15.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	22 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:5NX - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	14	2	2	3	1
12/31/2025	12	1	2	2	1
12/31/2024	9	0	2	2	1
6/30/2024	9	-1	-2	0	N/A
3/31/2024	9	-1	-3	-1	N/A
12/31/2023	9	-1	-4	-2	N/A
9/30/2023	8	-2	-4	-3	N/A
6/30/2023	6	-3	-4	-3	N/A
3/31/2023	9	-1	-2	-1	N/A
12/31/2022	11	1	0	1	N/A
9/30/2022	11	2	0	2	N/A
6/30/2022	12	3	0	2	N/A
3/31/2022	10	1	-2	0	N/A
12/31/2021	8	-1	-4	-2	N/A
9/30/2021	7	-2	-4	-3	N/A
6/30/2021	6	-4	-4	-3	N/A
3/31/2021	5	-4	-3	-3	N/A
12/31/2020	4	-4	-3	-3	N/A
9/30/2020	4	-4	-4	-4	N/A
6/30/2020	4	-4	-5	-5	N/A
3/31/2020	4	-6	-6	-6	N/A
12/31/2019	3	-7	-8	-7	N/A
9/30/2019	3	-7	-8	-7	N/A
6/30/2019	3	-7	-7	-7	N/A
3/31/2019	3	-7	-7	-6	N/A
12/31/2018	3	-6	-7	-6	N/A
9/30/2018	3	-6	-6	-6	N/A
6/30/2018	3	-6	-6	-6	N/A
3/31/2018	3	-7	N/A	-6	N/A
12/31/2017	3	-7	N/A	-5	N/A
9/30/2017	3	-7	N/A	-5	N/A
6/30/2017	3	-6	N/A	-5	N/A
3/31/2017	3	-6	N/A	-6	N/A
12/31/2016	3	-7	N/A	-7	N/A
9/30/2016	3	-8	N/A	-8	N/A
6/30/2016	3	-9	N/A	-10	N/A
3/31/2016	3	-10	N/A	-10	N/A
12/31/2015	3	-10	N/A	-10	N/A
9/30/2015	3	-10	N/A	-10	N/A
6/30/2015	3	-10	N/A	-11	N/A
3/31/2015	2	-10	N/A	-9	N/A
12/31/2014	2	-10	N/A	-8	N/A
9/30/2014	2	-9	N/A	-6	N/A
6/30/2014	2	-7	N/A	-5	N/A
3/31/2014	2	-6	N/A	-4	N/A
12/31/2013	2	-5	N/A	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 5NXは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1% ) よりも高い成長率であると考えられます。

収益対市場: 5NX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 5NX今後 3 年以内に収益を上げることが予想されます。

収益対市場: 5NXの収益 ( 15.7% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 5NXの収益 ( 15.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 5NXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Nexstim 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Nexstim Plc Updates Earnings Guidance for the Year 2023

Nexstim Plc Provides Earnings Guidance for the Year 2022

Forecast to breakeven in 2022

Recent updates

Nexstim Plc to Report Fiscal Year 2024 Results on Feb 27, 2025

Nexstim plc Receives Approval from Health Canada for the Marketing and Commercial Distribution of Its NBS 6 System for the Treatment of Major Depressive Disorder

Nexstim Plc Updates Earnings Guidance for the Year 2023

Nexstim Plc, Annual General Meeting, Mar 28, 2024

Nexstim Plc to Report Fiscal Year 2023 Final Results on Mar 06, 2024

Nexstim Plc Releases New System Functionalities for Research Use in Europe

Nexstim Plc to Report Q3, 2023 Results on Oct 27, 2023

Nexstim plc Announces Board Appointments

Nexstim Plc to Report Fiscal Year 2023 Results on Feb 27, 2024

Nexstim plc Provides Overview of Pilot Study Results in Treatment of Severe Depression with Nexstim Nbt®? System At Kuopio University Hospital

Nexstim Applies for Delisting Regarding the Secondary Listing of its Shares from Nasdaq First North Growth Market Sweden

Nexstim Plc, Annual General Meeting, Mar 31, 2023

Nexstim Reports Excellent Treatment Outcomes of over 400 MDD Patients in Patient Registry

Nexstim plc Appoints Tero Weckroth as A New Member of the Nomination Committee

First half 2022 earnings released

Nexstim Plc Provides Earnings Guidance for the Year 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Forecast to breakeven in 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Nexstim Reaches Over 300 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

Nexstim Plc Announces Results of the Pilot Study in Chronic Pain Treatment At Helsinki University Hospital

Nexstim Plc Receives System Orders from Existing Hospital Customers in Finland

Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital

First half 2021 earnings released: €0.17 loss per share (vs €1.25 loss in 1H 2020)

Nexstim Plc Provides Update on Pilot Study in Chronic Pain Treatment at Helsinki University Hospital

Nexstim Plc Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater Than 50%

Nexstim Plc Granted Authorization for Commercial Distribution of NBS System in Australia

Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder

Nexstim plc Receives Two NBS System Orders from Hospitals in Norway and the Us

Nexstim plc Provides Encouraging Results of the Initial Pilot Study in Severe Depression At Kuopio University Hospital

Full year 2020 earnings released

Revenue beats expectations

German University Hospital Orders Nexstim NBS System with NexSpeech

Rohan Hoare and Tomas Holmberg No Longer Be Available to Nexstim Plc's Board of Directors for the Period 2021-2022

Nexstim plc Receives Three New NBS System Orders

Nexstim Plc Receives Two New NBT® System Purchase Orders in the United States

Nexstim plc Provides an Update on the Pilot Study in Severe Depression At Kuopio University Hospital

Nexstim Plc Receives an Order and Signs Purchase Agreement to Develop Two Prototype Systems Enabling Introduction of Novel Research Tool for Probing and Diagnosing the Brain

Nexstim plc Continues to Report Promising Results in Quickly Growing Number of Patients Completing SmartFocus rTMS Treatment of Major Depressive Disorder

Pilot Study for New Depression Treatment Protocol with Nexstim NBT® System Starts in Kuopio University Hospital

Nexstim plc Receives Two Nbs System Upgrade Orders in the United States

Earnings released

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘